Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011-2016) [0.03%]
喹唑啉和喹唑啉酮作为重要的药物骨架：一项专利对比审查（2011-2016）
Abdul Hameed,Mariya Al-Rashida,Maliha Uroos et al.
Abdul Hameed et al.
Introduction: Quinazoline and quinazolinone scaffolds represent an important class of biologically active nitrogen heterocyclic compounds. A variety of marketed drugs are based on these moieties. A diverse range of molecu...
Therapeutic bispecific antibody formats: a patent applications review (1994-2017) [0.03%]
治疗性双特异性抗体格式：1994至2017年间专利申请综述
Marie Godar,Hans de Haard,Christophe Blanchetot et al.
Marie Godar et al.
Introduction: Bispecific antibodies have become increasingly of interest by enabling new therapeutic applications such as retargeting cellular immunity towards tumor cells. About 23 bispecific antibody platforms have ther...
Christopher L Cioffi
Christopher L Cioffi
Introduction: Numerous research groups have developed GlyT-1 inhibitors in the pursuit of providing a novel antipsychotic treatment for schizophrenia. Despite multiple compounds advancing into clinical trials, a GlyT-1 in...
Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017) [0.03%]
组胺H3受体拮抗剂/反向激动剂的研发进展（2013-2017）——专利回顾
Dorota Łażewska,Katarzyna Kieć-Kononowicz
Dorota Łażewska
Introduction: Since years, ligands blocking histamine H3 receptor (H3R) activity (antagonists/inverse agonists) are interesting targets in the search for new cures for CNS disorders. Intensive works done by academic and p...
An editorial on the article 'Patents in the Diabetes Area in the Years 2008-2016' [0.03%]
关于文章“糖尿病领域2008-2016年专利”的评论编辑稿
Sigurd Lenzen
Sigurd Lenzen
Simone Carradori,Daniela Secci,Jacques P Petzer
Simone Carradori
Introduction: Monoamine oxidase (MAO) inhibitors, after the initial 'golden age', are currently used as third-line antidepressants (selective MAO-A inhibitors) or clinically enrolled as co-adjuvants for neurodegenerative ...
Secondary patents in the pharmaceutical industry: missing the wood for the trees? [0.03%]
制药行业的二级专利：只见树木不见森林？
Saritha Kiran,Mohan Kulkarni
Saritha Kiran
Introduction: The critics of the Innovator pharmaceutical industry allege that secondary patents are trivial modifications over the primary patent, which extend its term and delay the entry of the generics in the market p...
K M Mohibul Kabir,William A Donald
K M Mohibul Kabir
Introduction: Human breath can contain thousands of volatile organic compounds (VOCs) and semi-volatile compounds that are related to metabolism and other biochemical processes. The presence of cancer cells can affect the...
Intellectual property considerations for molecular diagnostic development with emphasis on companion diagnostics [0.03%]
以伴随诊断为重点的分子诊断开发中的知识产权问题
Harry Glorikian,Richard Jeremy Warburg,Kelly Moore et al.
Harry Glorikian et al.
The development of molecular diagnostics is a complex endeavor, with multiple regulatory pathways to consider and numerous approaches to development and commercialization. Companion diagnostics, devices which are "essential for the safe and...
Peng-Cheng Lv,Ai-Qin Jiang,Wei-Ming Zhang et al.
Peng-Cheng Lv et al.
Introduction: Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that localizes at sites of cell adhesion to the extracellular matrix (ECM) and mediates signalling events downstream of integrin engagement of th...